Presence of phthalates in gastrointestinal medications: Is there a hidden danger?

World Journal of Gastroenterology

Volumn 19, Issue 41, 2013, Pages 7042-7047

  Gallinger, Zane R ^a   Nguyen, Geoffrey C ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 Aminosalicylates; Development; Dibutyl phthalate; Medications; Phthalates; Pregnancy

Indexed keywords

5 ACETAMIDOSALICYLIC ACID; MESALAZINE; OMEPRAZOLE; PHTHALIC ACID; PHTHALIC ACID DIBUTYL ESTER; PHTHALIC ACID DIETHYL ESTER; RANITIDINE; SALAZOSULFAPYRIDINE; BISACODYL; DI(2 ETHYL HEXYL)PHTHALATE; GASTROINTESTINAL AGENT; PANCREALIPASE; PANCREAS ENZYME; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

BIOSORPTION; CONTROLLED DRUG RELEASE; EXCIPIENT COMPATIBILITY; EXCRETION; GASTROINTESTINAL DISEASE; HUMAN; NONHUMAN; REPRODUCTIVE TOXICITY; REVIEW; SKELETON MALFORMATION; ULCERATIVE COLITIS; URINALYSIS; CHEMICAL STRUCTURE; DRUG FORMULATION; DRUG RELEASE; HEALTH STATUS; INFLAMMATORY BOWEL DISEASE; PREGNANT WOMAN; PRESCRIPTION;

5-AMINOSALICYLATES; DEVELOPMENT; DIBUTYL PHTHALATE; MEDICATIONS; PHTHALATES; PREGNANCY;

ANIMALS; DRUG CONTAMINATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; PATIENT SAFETY; PHTHALIC ACIDS; PLASTICIZERS; PREGNANCY; PREGNANCY COMPLICATIONS; RISK ASSESSMENT; RISK FACTORS;

EID: 84887535627     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i41.7042     Document Type: Review

References (59)

1. University of Massachusetts Lowell. Phthalates and their alternatives: Health and Environmental Concerns. Lowell: Lowell Center For Sustainable Production 2011; 31: 1-24
2. Wormuth M, Scheringer M, Vollenweider M, Hungerbühler K. What are the sources of exposure to eight frequently used phthalic acid esters in Europeans? Risk Anal 2006; 26: 803-824 [PMID: 16834635 DOI: 10.1111/j.1539-6924.2006.00770.x]
3. ATSDR (Agency for Toxic Substances and Disease Registry). Toxicological profile for Di (2-ethylhexyl) phthalate. Atlanta: US Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry; 2002
4. ATSDR (Agency for Toxic Substances and Disease Registry). Toxicological profile for Di-N-Butyl phthalate. Atlanta: US Department of Health and Human Services, Public Health Service, Agency for Toxic Substances and Disease Registry; 2002
5. Hernández-Díaz S, Mitchell AA, Kelley KE, Calafat AM, Hauser R. Medications as a potential source of exposure to phthalates in the U.S. population. Environ Health Perspect 2009; 117: 185-189 [PMID: 19270786 DOI: 10.1289/ehp.11766]
6. Wilkes CE, Summers JW, Daniels CA, Berard MT. PVC handbook. Cincinnati: Hanser Gardner Publications, 2005
7. Calafat AM, Silva MJ, Reidy JA, Earl Gray L, Samandar E, Preau JL, Herbert AR, Needham LL. Mono-(3-carboxypropyl) phthalate, a metabolite of di-n-octyl phthalate. J Toxicol Environ Health A 2006; 69: 215-227 [PMID: 16263692 DOI: 10.1080/15287390500227381]
8. Jurewicz J, Hanke W. Exposure to phthalates: reproductive outcome and children health. A review of epidemiological studies. Int J Occup Med Environ Health 2011; 24: 115-141 [PMID: 21594692 DOI: 10.2478/s13382-011-0022-2]
9. Keller BO, Davidson AG, Innis SM. Phthalate metabolites in urine of CF patients are associated with use of enteric-coated pancreatic enzymes. Environ Toxicol Pharmacol 2009; 27: 424-427 [PMID: 21783974 DOI: 10.1016/j.etap.2008.12.005]
10. Hauser R, Duty S, Godfrey-Bailey L, Calafat AM. Medications as a source of human exposure to phthalates. Environ Health Perspect 2004; 112: 751-753 [PMID: 15121520 DOI: 10.1289/ehp.6804]
11. Seckin E, Fromme H, Völkel W. Determination of total and free mono-n-butyl phthalate in human urine samples after medication of a di-n-butyl phthalate containing capsule. Toxicol Lett 2009; 188: 33-37 [PMID: 19433267 DOI: 10.1016/ j.toxlet.2009.03.002]
12. Hauser R, Calafat AM. Phthalates and human health. Occup Environ Med 2005; 62: 806-818 [PMID: 16234408 DOI: 10.1136/oem.2004.017590]
13. Fromme H, Bolte G, Koch HM, Angerer J, Boehmer S, Drexler H, Mayer R, Liebl B. Occurrence and daily variation of phthalate metabolites in the urine of an adult population. Int J Hyg Environ Health 2007; 210: 21-33 [PMID: 17182278 DOI: 10.1016/j.ijheh.2006.09.005]
14. Silva MJ, Barr DB, Reidy JA, Malek NA, Hodge CC, Caudill SP, Brock JW, Needham LL, Calafat AM. Urinary levels of seven phthalate metabolites in the U.S. population from the National Health and Nutrition Examination Survey (NHANES) 1999-2000. Environ Health Perspect 2004; 112: 331-338 [PMID: 14998749 DOI: 10.1289/ehp.6723]
15. Becker K, Seiwert M, Angerer J, Heger W, Koch HM, Nagorka R, Rosskamp E, Schlüter C, Seifert B, Ullrich D. DEHP metabolites in urine of children and DEHP in house dust. Int J Hyg Environ Health 2004; 207: 409-417 [PMID: 15575555 DOI: 10.1078/1438-4639-00309]
16. Rowe RC, Sheskey PJ, Quinn M. Handbook of pharmaceutical excipients with CD-ROM. 2009
17. Kelley KE, Hernández-Díaz S, Chaplin EL, Hauser R, Mitchell AA. Identification of phthalates in medications and dietary supplement formulations in the United States and Canada. Environ Health Perspect 2012; 120: 379-384 [PMID: 22169271 DOI: 10.1289/ehp.1103998]
18. Crowley P, Martini LG. Drug-excipient interactions. Pharm Technol 2001; 4: 7-12
19. Betts KS. Phthalates in Prescription Drugs: Some Medications Deliver High Doses. Environ Health Perspect 2009; 117: A74
20. Limiting the use of certain phthalates as excipients in CDERregulated products [Internet]. 2012, cited 2013 March 23. Available from: URL: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM294086.pdf
21. Chilcott W. Asacol full prescribing information [Internet]. 2010, cited 2013 March 23. Available from: URL: http:// www.asacolhd.com/ pdfs/AsacolHDPrescribingInfo.pdf
22. Durmaz E, Ozmert EN, Erkekoglu P, Giray B, Derman O, Hincal F, Yurdakök K. Plasma phthalate levels in pubertal gynecomastia. Pediatrics 2010; 125: e122-e129 [PMID: 20008419 DOI: 10.1542/peds.2009-0724]
23. Swan SH. Environmental phthalate exposure in relation to reproductive outcomes and other health endpoints in humans. Environ Res 2008; 108: 177-184 [PMID: 18949837 DOI: 10.1001/archpediatrics.2012.241]
24. Nomura Y, Mitsui N, Bhawal UK, Sawajiri M, Tooi O, Takahashi T, Okazaki M. Estrogenic activity of phthalate esters by in vitro VTG assay using primary-cultured Xenopus hepatocytes. Dent Mater J 2006; 25: 533-537 [PMID: 17076324 DOI: 10.4012/dmj.25.533]
25. Wolf C, Lambright C, Mann P, Price M, Cooper RL, Ostby J, Gray LE. Administration of potentially antiandrogenic pesticides (procymidone, linuron, iprodione, chlozolinate, p, p'-DDE, and ketoconazole) and toxic substances (dibutyland diethylhexyl phthalate, PCB 169, and ethane dimethane sulphonate) during sexual differentiation produces diverse profiles of reproductive malformations in the male rat. Toxicol Ind Health 1999; 15: 94-118 [PMID: 10188194 DOI: 10.1177/074823379901500109]
26. Wolff MS, Engel SM, Berkowitz GS, Ye X, Silva MJ, Zhu C, Wetmur J, Calafat AM. Prenatal phenol and phthalate exposures and birth outcomes. Environ Health Perspect 2008; 116: 1092-1097 [PMID: 18709157 DOI: 10.1289/ehp.11007]
27. Main KM, Mortensen GK, Kaleva MM, Boisen KA, Damgaard IN, Chellakooty M, Schmidt IM, Suomi AM, Virtanen HE, Petersen DV, Andersson AM, Toppari J, Skakkebaek NE. Human breast milk contamination with phthalates and alterations of endogenous reproductive hormones in infants three months of age. Environ Health Perspect 2006; 114: 270-276 [PMID: 16451866 DOI: 10.1289/ehp.8075]
28. Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Calafat AM, Mao CS, Redmon JB, Ternand CL, Sullivan S, Teague JL. Decrease in anogenital distance among male infants with prenatal phthalate exposure. Environ Health Perspect 2005; 113: 1056-1061 [PMID: 16079079 DOI: 10.1289/ehp.8100]
29. Bustamante-Montes LP, Hernández-Valero MA, Garcia-Fabila M, Halley-Castillo E, Karam-Calderon MA, Borja-Aburto VH. Prenatal phthalate exposure and decrease in ano-Genital distance in mexican male newborns. Epidemiology 2008; 19: S270 [DOI: 10.1017/S2040174413000172]
30. Duty SM, Silva MJ, Barr DB, Brock JW, Ryan L, Chen Z, Herrick RF, Christiani DC, Hauser R. Phthalate exposure and human semen parameters. Epidemiology 2003; 14: 269-277 [PMID: 12859026 DOI: 10.1097/01. EDE.0000059950.11836.16]
31. Hauser R, Meeker JD, Duty S, Silva MJ, Calafat AM. Altered semen quality in relation to urinary concentrations of phthalate monoester and oxidative metabolites. Epidemiology 2006; 17: 682-691 [PMID: 17003688 DOI: 10.1097/01. ede.0000235996.89953.d7]
32. Hauser R, Meeker JD, Singh NP, Silva MJ, Ryan L, Duty S, Calafat AM. DNA damage in human sperm is related to urinary levels of phthalate monoester and oxidative metabolites. Hum Reprod 2007; 22: 688-695 [PMID: 17090632 DOI: 10.1093/humrep/del428]
33. Jönsson BA, Richthoff J, Rylander L, Giwercman A, Hagmar L. Urinary phthalate metabolites and biomarkers of reproductive function in young men. Epidemiology 2005; 16: 487-493 [PMID: 15951666 DOI: 10.1097/01.ede.0000164555.19041.01]
34. Wirth JJ, Rossano MG, Potter R, Puscheck E, Daly DC, Paneth N, Krawetz SA, Protas BM, Diamond MP. A pilot study associating urinary concentrations of phthalate metabolites and semen quality. Syst Biol Reprod Med; 54: 143-154 [PMID: 18570050 DOI: 10.1080/19396360802055921]
35. Cho SC, Bhang SY, Hong YC, Shin MS, Kim BN, Kim JW, Yoo HJ, Cho IH, Kim HW. Relationship between environmental phthalate exposure and the intelligence of schoolage children. Environ Health Perspect 2010; 118: 1027-1032 [PMID: 20194078 DOI: 10.1289/ehp.0901376]
36. Engel SM, Miodovnik A, Canfield RL, Zhu C, Silva MJ, Calafat AM, Wolff MS. Prenatal phthalate exposure is associated with childhood behavior and executive functioning. Environ Health Perspect 2010; 118: 565-571 [PMID: 20106747 DOI: 10.1289/ehp.0901470]
37. Boas M, Feldt-Rasmussen U, Skakkebaek NE, Main KM. Environmental chemicals and thyroid function. Eur J Endocrinol 2006; 154: 599-611 [PMID: 16645005 DOI: 10.1530/ eje.1.02128]
38. Kim BN, Cho SC, Kim Y, Shin MS, Yoo HJ, Kim JW, Yang YH, Kim HW, Bhang SY, Hong YC. Phthalates exposure and attention-deficit/hyperactivity disorder in school-age children. Biol Psychiatry 2009; 66: 958-963 [PMID: 19748073 DOI: 10.1016/j.biopsych.2009.07.034]
39. Lomenick JP, Calafat AM, Melguizo Castro MS, Mier R, Stenger P, Foster MB, Wintergerst KA. Phthalate exposure and precocious puberty in females. J Pediatr 2010; 156: 221-225 [PMID: 19892364 DOI: 10.1016/j.jpeds.2009.09.047]
40. Larsson M, Hägerhed-Engman L, Kolarik B, James P, Lundin F, Janson S, Sundell J, Bornehag CG. PVC--as flooring material--and its association with incident asthma in a Swedish child cohort study. Indoor Air 2010; 20: 494-501 [PMID: 21070375 DOI: 10.1111/j.1600-0668.2010.00671.x]
41. Bornehag CG, Sundell J, Hagerhed-Engman L, Sigsggard T, Janson S, Aberg N. 'Dampness' at home and its association with airway, nose, and skin symptoms among 10,851 preschool children in Sweden: a cross-sectional study. Indoor Air 2005; 15 Suppl 10: 48-55 [PMID: 15926944 DOI: 10.1111/ j.1600-0668.2005.00306.x]
42. Jaakkola JJ, Parise H, Kislitsin V, Lebedeva NI, Spengler JD. Asthma, wheezing, and allergies in Russian schoolchildren in relation to new surface materials in the home. Am J Public Health 2004; 94: 560-562 [PMID: 15054004 DOI: 10.2105/ AJPH.94.4.560]
43. Jaakkola JJ, Verkasalo PK, Jaakkola N. Plastic wall materials in the home and respiratory health in young children. Am J Public Health 2000; 90: 797-799 [PMID: 10800434 DOI: 10.2105/AJPH.90.5.797]
44. Huang PC, Kuo PL, Chou YY, Lin SJ, Lee CC. Association between prenatal exposure to phthalates and the health of newborns. Environ Int 2009; 35: 14-20 [PMID: 18640725 DOI: 10.1016/j.envint.2008.05.012]
45. Högberg J, Hanberg A, Berglund M, Skerfving S, Remberger M, Calafat AM, Filipsson AF, Jansson B, Johansson N, Appelgren M, Håkansson H. Phthalate diesters and their metabolites in human breast milk, blood or serum, and urine as biomarkers of exposure in vulnerable populations. Environ Health Perspect 2008; 116: 334-339 [PMID: 18335100]
46. Silva MJ, Reidy JA, Herbert AR, Preau JL, Needham LL, Calafat AM. Detection of phthalate metabolites in human amniotic fluid. Bull Environ Contam Toxicol 2004; 72: 1226-1231 [PMID: 15362453 DOI: 10.1007/s00128-004-0374-4]
47. Diav-Citrin O, Park YH, Veerasuntharam G, Polachek H, Bologa M, Pastuszak A, Koren G. The safety of mesalamine in human pregnancy: a prospective controlled cohort study. Gastroenterology 1998; 114: 23-28 [PMID: 9428214 DOI: 10.1016/S0016-5085(98)70628-6]
48. Nørgård B, Fonager K, Pedersen L, Jacobsen BA, Sørensen HT. Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study. Gut 2003; 52: 243-247 [PMID: 12524407 DOI: 10.1136/gut.52.2.243]
49. Nørgård B, Pedersen L, Christensen LA, Sørensen HT. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 2007; 102: 1406-1413 [PMID: 17437503 DOI: 10.1111/j.1572-0241.2007.01216.x]
50. Moskovitz DN, Bodian C, Chapman ML, Marion JF, Rubin PH, Scherl E, Present DH. The effect on the fetus of medications used to treat pregnant inflammatory bowel-disease patients. Am J Gastroenterol 2004; 99: 656-661 [PMID: 15089898 DOI: 10.1111/j.1572-0241.2004.04140.x]
51. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol 2008; 25: 271-275 [PMID: 18242053 DOI: 10.1016/j.reprotox.2007.11.010]
52. Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75; quiz 432-3 [PMID: 17241860 DOI: 10.1053/j.gastro.2006.10.011]
53. Consumer product safety improvement act (CPSIA), section 108 [Internet]. 2008, cited 2013 Jan 25. Available from: URL: http://www.cpsc.gov/cpsia.pdf
54. Directive 2005/90/EC of the European Parliament and of the Council of 18 January 2006 amending, for the 29th time, Council Directive 76/769/EEC on the approximation of the laws, regulations, and administrative provisions of the Member States relating to restrictions on the marketing and use of certain dangerous substances and preparations. OJEU 2006: Apr 2
55. Robert B. Toxciological review of dibutyl phthalate (Di-nbutyl phthalate) [Internet]. 2006, cited 2013 Jan 25. Available from: URL: http://cfpub.epa.gov/ncea/iris_drafts/recordisplay. cfm?deid=155707
56. DEHP in Plastic Medical Devices [Internet]. 2009, cited 2013 Jan 25. Available from: URL: http://www.fda.gov/MedicalDevices/ ResourcesforYou/Consumers/ChoosingaMedicalDevice/ucm142643.htm
57. Order amending schedule I to the hazardous products act (Phthalates). Canada Gazette [Internet]. 2010; cited 2013 Jan 25; 144. Available from: URL: http://gazette.gc.ca/rp-pr/ p2/2010/2010-12-22/html/sor-dors297-eng.html#1
58. Nguyen GC. Phthalates in 5-Aminosalicylates. J Curr Clin Care 2012; 14-21
59. Consumer Health Products Associations. The new over the counter medicine label [pamphlet]. New Jersey: Schering Plough, 2003